The FINEARTS-HF trial is a phase II study currently investigating the benefit of finerenone on cardiovascular death and HF in patients with HFpEF with or without type 2 diabetes, whereas the MIRACLE trial is a phase II study investigating the MR modulator AZD9977 on top of the SGLT2i dapaglifozin in patients with HF with LVEF ≥ 40% and CKD. Here, NR3C2 is linked to type 2 diabetes mellitus.